ERBB2 and breast carcinoma: In a pooled analysis of almost 6,500 patients with breast cancer receiving neoadjuvant therapy 13, pathological complete response was associated with increased disease-free survival (hazard ratio=0.446), and this correlation was greater in patients with triple-negative or HER2-positive breast cancers.